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Abstract: As the life expectancy of β
last decade, several new complications are being recognized. The presence of a high incidence 
of  thromboembolic  events,  mainly  in  thalassemia  intermedia  patients,  has  led  to  the 
identification of a hypercoagulable state in thalassemia. In this review, the molecular and 
cellular  mechanisms leading  to hypercoagulability  in  thalassemia are highlighted,  and  the 
current clinical experience is summarized. Recommendations for thrombosis prophylaxi
also discussed.
Introduction:  Although  once  considered  a  fatal 
disease,  the  life  expectancy  of  thalassemia  major 
(TM) patients has markedly improved over the last 
few years, as a result of regular blood transfusions 
and compliance with tight iron chelation therapy
However,  TM  patients  still  suffer  from  many 
complications of their chronic disease, and a series 
of serious previously undescribed complications are 
now  being  acknowledged,  including  thrombosis
Patients with thalassemia intermedia (TI) have, in 
general, a milder clinical phenotype than those with 
TM  and  remain  largely  transfusion  independent
The  pathophysiology  of  TI  is  characterized  by 
extravascular  hemolysis,  with  the  release  into  the 
peripheral  circulation  of  damaged  red  blood  cells 
(RBCs) and erythroid precursors because of a high 
degree of ineffective erythropoiesis
; Open Journal System 
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expectancy of β-thalassemia patients has markedly improved over the 
last decade, several new complications are being recognized. The presence of a high incidence 
of  thromboembolic  events,  mainly  in  thalassemia  intermedia  patients,  has  led  to  the 
tion of a hypercoagulable state in thalassemia. In this review, the molecular and 
cellular  mechanisms leading  to hypercoagulability  in  thalassemia are highlighted,  and  the 
current clinical experience is summarized. Recommendations for thrombosis prophylaxi
Although  once  considered  a  fatal 
disease,  the  life  expectancy  of  thalassemia  major 
(TM) patients has markedly improved over the last 
years, as a result of regular blood transfusions 
and compliance with tight iron chelation therapy.
1
,  TM  patients  still  suffer  from  many 
complications of their chronic disease, and a series 
of serious previously undescribed complications are 
now  being  acknowledged,  including  thrombosis.
2
ssemia intermedia (TI) have, in 
general, a milder clinical phenotype than those with 
TM  and  remain  largely  transfusion  independent
3. 
The  pathophysiology  of  TI  is  characterized  by 
extravascular  hemolysis,  with  the  release  into  the 
peripheral  circulation  of  damaged  red  blood  cells 
ecursors because of a high 
degree of ineffective erythropoiesis
2. This has also 
been  recently  attributed  to  severe  complications 
such  as  pulmonary  hypertension  (PHT)  and 
thromboembolic  phenomena
summarises current knowledge of the clinical and 
pathophysiological  characteristics  of  hyper
coagulability in thalassemia patients and highlights 
available  strategies  to  prevent  the  associated 
thromboemoblic events (TEE).
Pathogenesis:  Guided  by  clinical  observation, 
diverse factors contributing to the hypercoagulable 
state  in  patients  with  thalassemia  have  been 
identified (Figure 1).
2 In most cases, a combin
of these abnormalities leads to clinical thrombosis. 
Among  cellular  factors
contributes  to  a  significant  extent.  The  medical 
literature is rich in evidence suggesting that patients 
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thalassemia patients has markedly improved over the 
last decade, several new complications are being recognized. The presence of a high incidence 
of  thromboembolic  events,  mainly  in  thalassemia  intermedia  patients,  has  led  to  the 
tion of a hypercoagulable state in thalassemia. In this review, the molecular and 
cellular  mechanisms leading  to hypercoagulability  in  thalassemia are highlighted,  and  the 
current clinical experience is summarized. Recommendations for thrombosis prophylaxis are 
been  recently  attributed  to  severe  complications 
such  as  pulmonary  hypertension  (PHT)  and 
thromboembolic  phenomena.
2 This  review 
summarises current knowledge of the clinical and 
pathophysiological  characteristics  of  hyper-
coagulability in thalassemia patients and highlights 
available  strategies  to  prevent  the  associated 
events (TEE).
Guided  by  clinical  observation, 
diverse factors contributing to the hypercoagulable 
state  in  patients  with  thalassemia  have  been 
In most cases, a combination 
of these abnormalities leads to clinical thrombosis. 
Among  cellular  factors,  platelet  activation
contributes  to  a  significant  extent.  The  medical 
literature is rich in evidence suggesting that patients Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Figure 1. Factors contributing to hypercoagulability in thalassemia (RBCs = red blood cells)
2.
with thalassemia have activated platelets. Moreover, 
flow  cytometric  studies  have  also  confirmed  the 
chronic  platelet  activation  status.  In  thalassemia, 
there is evidence of increased platelet aggregation,
4
an  increased  proportion  of  platelets  expressing 
CD62P (P-selectin) and CD63,
5-6 and  a shortened 
platelet  survival  due  to  enhanced  platelet 
consumption  (especially  in  splenectomized 
patients).
7-8
Alteration  in  RBCs,  namely  the  oxidation  of 
globin subunits in thalassemia erythroid cells, leads 
to  the  formation  of  hemichromes.  Hemichromes 
bind to or modify various components of the mature 
RBC membrane, such as protein band 3, ankyrin, 
and  spectrin.  After  the  precipitation  of 
hemichromes,  heme  disintegrates,  and  toxic 
nontransferrin-bound iron species are released from 
the  heme  disintegration.  The  resulting  free  iron 
catalyzes the formation of reactive oxygen species. 
Iron-dependent oxidation of membrane proteins and 
formation of red-cell  ‘‘senescence’’ antigens such 
as phosphatidylserine cause thalassemic red cells to 
be rigid and deformed and to aggregate, resulting in 
premature cell removal.
9-13 Studies have shown that 
thalassemic RBCs may be  a  source  of  negatively 
charged  phospholipids,  which  can  eventually 
increase thrombin generation.
14-15 This was verified 
by  experiments  that  showed  that  annexin  V,  a 
protein with high affinity and specificity for anionic 
phospholipids, could block the procoagulant effect 
of  isolated  thalassemic  RBCs.
15-16 Several  studies 
have  demonstrated  that  RBCs  from  thalassemic 
patients  also  show  enhanced  cohesiveness  and 
aggregability.  These  abnormalities  have  been 
reduced  to  normal  range  after  the  patients  have 
received a blood transfusion.
15
The  finding  of  elevated  levels  of  endothelial
adhesion  proteins  (E-selectin  [ELAM-1], 
intercellular  adhesion  molecule-1  [ICAM-1]  and 
von  Willebrand  factor  [VWF])  and  vascular  cell 
adhesion  molecule-1  [VCAM-1]  in  thalassemic 
patients  suggested  that  endothelial  injury  or 
activation may be a feature of this genetic disease 
which  also  plays  an  important  role  in  the 
recruitment  of  white  blood  cells  and  RBCs  and 
promote thrombosis at vascular inflammation sites, 
vessel  obstruction,  tissue  hypoxia  and  death
17-22. 
More recently, it was shown that microparticles of 
red blood cell origins were elevated in patients with
TI vs. controls; these have a potential to aggravateMedit J Hemat Infect Dis 2009; 1; Open Journal System 
Table 1. Prevalence of thromboembolic events in patients with thalassemia major and intermedia.
TI  =  thalassemia  intermedia,  TM  =  thalassemia  major,  VT  =  venous  thrombosis,  PE  =  pulmonary  embolism,  AT  =  arterial 
thrombosis, N/A = not available.
thrombotic events.
23
Clinical  observations  have  suggested  that 
splenectomy  in  TI  can  contribute  to  an  increased 
susceptibility  to  thrombosis.
24-26 The  development 
of  these  complications  has  been  ascribed  to  the 
presence  of  high  platelet  counts  following 
splenectomy  and/or  to  increased  number  of 
abnormal RBCs.
27-29 In splenectomized TI patients, 
thrombin  generation  was significantly  higher than 
in  control  subjects  and  patients  who  had not 
undergone splenectomy.
26 From the available data, 
DNA mutations do not appear to play an important 
role in the pathogenesis of thrombosis observed in 
thalassemia.  In  two  studies  from  the  Eastern 
Mediterranean  region  the  presence  of  factor  V 
Leiden,  prothrombin  mutation,  and  methylene 
tetrahydrofolate reductase (MTHFR) mutations was 
not  significantly  correlated  with  the  thrombotic 
risk.
30-31 However, many investigators have reported 
changes  in  the  levels  of  coagulation  factors  and 
inhibitors  in  thalassemic  patients.  Prothrombin 
fragment  1.2  (F1.2),  a  marker  of  thrombin 
generation, is elevated in TI patients. The status of 
protein  C  and  protein  S  was  investigated  in 
thalassemia  in  many  studies  and  generally  they 
were  found  to  be  decreased;  this  might  be 
responsible  for  the  occurrence  of  TEE  in 
thalassemic  patients.
26 The  presence  of  anti-
phospholipid antibodies (aPL) has been reported in 
the  serum  of  thalassemia  patients.  However,  the 
exact nature of these antibodies and their relation to 
coexistent hepatitis C virus (HCV) infection is still 
under  investigation.
32 Other  pathogenetic 
mechanisms  have  been  correlated  with 
hypercoagulability in thalassemia and these include 
cardiac  dysfunction,  hormonal  deficiencies  and 
liver dysfunction.
2
The  pathophysiological roles of hemolysis  and 
the  dysregulation  of  nitric  oxide  homeostasis  are 
correlated  with  pulmonary  hypertension  in  sickle 
cell disease and in thalassemia. Nitric oxide binds 
soluble guanylate cyclase, which converts GTP to 
cGMP,  relaxing  vascular  smooth  muscle  and 
causing  vasodilatation.  When  plasma  hemoglobin 
liberated  from  intravascularly  hemolyzed  sickle 
erythrocytes consumes nitric oxide, the balance is 
shifted  toward  vasoconstriction.  Pulmonary 
hypertension  is  aggravated  and  in  sickle  cell 
disease, it is linked to the intensity of hemolysis. 
Whether  the  same  mechanism  contributes  to 
hypercoagulability in thalassemia is not yet known 
and needs to be investigated.
33
Clinical  Impact: There  are  relatively  few 
epidemiological  data  on  the  overall  frequency  of 
TEE  in  patients  with  thalassemia (Table  1).  The 
largest clinical study to date
25 analyzed data from 
8860 thalassemia patients (6670 TM and 2190 TI). 
The authors demonstrated that TEE occurred 4.38 
times more frequently in TI than TM (p < 0.001), 
with more venous events occurring in TI and more 
arterial events occurring in TM. Moreover, patients 
with  TI  who  developed  a  TEE  were  mostly 
splenectomized,  non-transfused,  and  had  a 
haemoglobin  level  below  9  g/dl.  The  study 
described age beyond 20 years, splenectomy, family 
history of TEE and previous TEE as the main risk 
factors  for  developing  thrombosis  in  the  study 
group.
25 In another series of TI patients, 24 patients 
(29%)  developed  either  deep  vein  thrombosis 
Reference
TI
n (%)
TM
n (%)
Type of thrombosis
VT PE AT Stroke
Michaeli et al, 1992
38 - 4/100 (4) * * * *
Aessopos J et al, 1997
45 3/5 (60) 3/5 (60) *
Moratelli et al, 1998
46 12/74 (16.2) 14/421 (3.3) N/A
Borgna Pignatti et al, 
1998
35 5/52 (9.6) 27/683 (4.0) * * * *
Cappellini et al, 2000
26 24/83 (29) - * * *
Taher et al, 2006
25 85/2190 (3.9) 61/6670 (0.9) * * * *Medit J Hemat Infect Dis 2009; 1; Open Journal System 
(DVT),  pulmonary  embolism,  or  portal  vein 
thrombosis  during  a  10-year  follow  up.
26 All 
patients   except one had undergone splenectomy. A 
study  on  survival  and  causes  of  death  in  TM, 
carried out in Italy at the end of the 1980s, indicated 
TEE as the primary cause of death in four of 159 
(2.5%)  transfusion-dependent  thalassemic 
patients.
34 In a recent survey involving nine Italian 
pediatric thalassemia centers, TEE was observed in 
4%  of  683  patients  with  TM  and  in  9.6%  of  52 
patients with TI.
35 Even more recently, data from 
seven Italian centers on 720 patients with TM, 1.1% 
of the patients had thrombosis.
1  
Logothetis et al. described a “stroke syndrome” 
and neurological deficits compatible with transient 
ischemic attacks (TIAs) in about 20% of 138 cases 
of TM in Greece.
36 Similarly, Borgna Pignatti et al. 
described TIAs accompanied by a clinical picture of 
headache, seizures, and hemiparesis in 2.2% of TM 
patients in Italy.
35 Although the incidence of overt 
stroke in TM was usually described as higher than 
TI,
25 a study done to assess the rate of silent brain 
damage in patients with benign hemoglobinopathies 
reported  that  37.5%  of  patients  with  TI  showed 
asymptomatic  brain  damage  on  brain  magnetic 
resonance imaging (MRI)
37. More recently, a brain 
MRI  study  on  adult,  splenectomized  TI  patients 
showed a rate of silent white matter lesions as high 
as 60%.
24 Older age and transfusion naivety were 
associated with a higher incidence and multiplicity 
of lesions.
24
Autopsy  series  in  patients  with  TM  and  TI 
describe the presence of DVT, pulmonary embolism 
and  recurrent  arterial  occlusion,  with  thrombi  in 
small and large pulmonary vessels.
34,38-39 Autopsies 
of  a  large  series  of  patients  with  Beta-
thalassemia/hemoglobin  E  disease  revealed 
thrombotic  lesions  in  the  pulmonary  arteries.
40
These  pulmonary  arterial  thromboembolism  may 
have  been  due  to  circulating  platelet  aggregates. 
Similar  findings  of  multiple  microthrombi,  which 
were composed mainly of platelets, were seen in the 
pulmonary  arterioles  and  microcirculation  in 
autopsies  of  two  splenectomized  patients  with 
thalassemia.
41 The  aforementioned  collective 
evidence  allowed  the  identification  of TEE  as  an 
established  complication  of  thalassemia,  which  is 
now referred to as a ‘hypercoagulable state’.
42
Recommendations for Management: The higher 
rate  of  thrombosis  in  transfusion-independent  TI 
compared to polytransused TM patients suggests a 
potential role for transfusions in decreasing the rate 
of TEE.
24-26,35 The reduction of TEE in adequately 
transfused patients may be the result of decreased 
numbers of pathological RBCs exhibiting indices of 
membrane  damage.
16 It  should  be  noted  that  the 
benefit of regular blood transfusions is appreciated 
in  the  more  frequent  thromboembolic 
manifestations  in  less  developed  countries  with 
inadequate  transfusion  resources.  Moreover,  the 
higher rate of TEE in splenectomized patients may 
alter the risk-benefit assessment of splenectomy as a 
procedure of choice. The available data on the use 
of  anticoagulants,  antiplatelet,  or  other  agents  in 
thalassemia  are  either  lacking  or  involve  small, 
poorly  controlled  and/or  relatively  low-quality 
studies.
2 However, TI patients who experienced a 
TEE  and received  aspirin afterwards  had a  lower 
recurrence of TEE compared with those who were 
not taking aspirin, although these differences were 
not statistically significant.
25
Treatment  with  the  fetal  hemoglobin-inducing 
agents,  hydroxycarbmide  and  decitabine,  results 
decreased plasma markers of thrombin generation. 
Hydroxycarbamide,  specifically  approved  for  the 
treatment  of  sickle  cell  disease,  may  decrease 
coagulation  activation  by  reducing  phospholipid 
expression  on  the  surface  of  both  RBCs  and 
platelets  and  decreasing  RBC  adhesion  to 
thrombospondin.  In addition to being a nitric oxide 
donor,  hydroxycarbamide  may  also  decrease 
hemostatic activation by its effect in decreasing the 
white blood cell count and particularly monocytes 
that  express  transcription  factor
33.  
Hydroxycarbamide  is  only  rarely  used  in 
thalassemia
43,  these  patients  may  experience  the 
benefits  because of similar mechanisms  described 
in sickle cell disease. Another approach would be to 
correct  the  reactive  oxygen  species-induced  RBC 
membrane damage using antioxidants, although this 
approach has not yet been verified in clinical trials.
It may also be possible to design a thalassemia-
tailored thrombosis risk-assessment  model (RAM) 
to estimate thrombotic risk as a function of intrinsic 
(e.g.  thalassemia  type  and  number  of  circulating 
RBC)  and  extrinsic  (e.g.  infection,  surgery,  and 
splenectomy)  factors.  Moreover,  tests  for 
predisposing  factors  could  also  be  performed, 
particularly  in  high-risk  patients.  If  clinically 
verified,  this  type  of  model  could  serve  as  a 
guideline  for  possible  preventative  treatment  to 
decrease  the  incidence  of  TEE,  which  can  cause 
significant  morbidity  and  mortality.
2 In  fact, 
attempts to identify diagnostic tests that will help 
identify patients at risk are emerging
44, with results 
that are promising towards establishing an evidence 
based preventive approach.Medit J Hemat Infect Dis 2009; 1; Open Journal System 
Conclusion: In conclusion, there are diverse factors 
contributing to the hypercoagulable state observed 
in  patients  with  thalassemia.  In  most  cases,  a 
combination of these abnormalities leads to clinical 
thrombosis.  The  higher  incidence  of  thrombotic 
events  in  TI  compared  to  TM  patients  is  mainly 
attributed to transfusion naivety and splenectomy, 
both of which promote an underlying procoagulant 
activity.  Although  no  clear  guidelines  exist  to 
establish a prophylactic strategy, an individualized 
approach that takes into consideration all associated 
risk factors is advisable.
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